Quarterly ResultNov 10, 2026, 05:31 PM
Capricor Therapeutics Reports Q3 2026 Net Loss of $42.66M
AI Summary
Capricor Therapeutics, Inc. reported its third-quarter financial results for 2026, showing a widening net loss of $42.66 million compared to $24.57 million in the prior year's quarter. For the nine-month period, the net loss also increased to $117.33 million from $74.87 million. Operating expenses rose significantly, driven by increased research and development costs. The company's cash position saw a substantial decrease, while its marketable securities portfolio grew.
Key Highlights
- Capricor Therapeutics reported a net loss of $42.66 million for Q3 2026, compared to $24.57 million in Q3 2025.
- For the nine months ended September 30, 2026, the net loss was $117.33 million, up from $74.87 million in the same period of 2025.
- Total operating expenses increased to $44.68 million in Q3 2026 from $26.28 million in Q3 2025.
- Research and development expenses for the nine months ended September 30, 2026, were $85.80 million, an increase from $61.32 million in 2025.
- Cash and cash equivalents decreased significantly to $44.28 million as of September 30, 2026, from $287.85 million as of December 31, 2025.
- Marketable securities increased to $153.30 million as of September 30, 2026, from $30.28 million as of December 31, 2025.
Price Impact
More from CAPR